Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO

Participants needed: 910
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Kodiak Sciences IncUpdated: Aug 21, 2026Locations: 9
Eligibility criteria

DME, treatment-naïve or previously-treated [+2]

Active iris or angle neovascularization or neovascular glaucoma in the Study Eye... [+1]

Status: Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Participants needed: 300
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Kodiak Sciences IncUpdated: May 18, 2026Locations: 56
Eligibility criteria

Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness... [+2]

ME in the Study Eye secondary to diabetes, RVO, or wAMD. [+2]

Status: Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Kodiak Sciences IncUpdated: May 18, 2026Locations: 56
Eligibility criteria

Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness... [+3]

Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD. [+2]